TOP1 and neoplasm: Elegant studies have documented a number of mechanisms utilized by tumor cells to become resistant to TOP1 inhibitors, such as upregulation or mutation of the proteins involved in drug efflux and mutations in the TOP1 protein [9,10,11,12,13].